How Long Can You Do Immunotherapy?

Immunotherapy treatment for cancer has no universally agreed-upon stopping point. Many clinical trials use a two-year benchmark, but the medical community has not reached a clear consensus on the optimal duration, and real-world treatment can last anywhere from a few months to well beyond two years depending on the cancer type, the patient’s response, and whether side effects intervene.¹ The question of when to stop is one of the most actively debated in oncology right now, and the answer your doctor gives you will depend on a tangle of factors that are still being sorted out by ongoing research.

What the Trials Actually Show

The best direct comparison we have between a fixed treatment period and open-ended treatment comes from a large lung cancer trial called CheckMate 153. Patients with advanced non-small-cell lung cancer who continued receiving nivolumab indefinitely did substantially better than those who stopped after one year. Median progression-free survival was roughly 25 months in the continuous group versus about 9 months in those who stopped at one year, and overall survival was also longer with ongoing treatment.² That result pushed many oncologists away from a strict one-year cutoff for lung cancer patients who were tolerating treatment well.

Melanoma tells a somewhat different story. A large study using real-world data from advanced melanoma patients tried to emulate what would happen if treatment were stopped at various time points. Stopping immunotherapy early, before a patient had received at least a few months of treatment, was clearly harmful: the 48-month survival difference was nearly 38 percentage points worse for those who discontinued early compared to those who continued for at least three more months. But at the 24-month mark, stopping treatment actually appeared favorable. Patients who discontinued at around two years had an absolute 48-month survival rate that was about 10 percentage points higher than those who kept going.³ At 12 and 18 months, there was no clear advantage either way.

These two findings illustrate why there is no one-size-fits-all answer. In lung cancer, stopping at one year looked premature. In melanoma, two years seemed to be a reasonable stopping point for many patients. The cancer type, how deeply the tumor has responded, and whether the disease has been completely cleared on imaging all play into the decision.

Why Most Oncologists Use Two Years as a Starting Point

The two-year figure comes partly from the landmark trials of drugs like pembrolizumab and nivolumab, where treatment was capped at two years by protocol design. Patients who achieved a complete response or near-complete response by that point generally did well after stopping, and that observation became a practical rule of thumb. But it was never a rule backed by hard proof that two years was the optimal duration for everyone. It was simply the duration the trials tested.

In practice, many oncologists feel comfortable stopping at two years for patients whose scans show a complete response or a strong partial response that has been stable for a long time. For patients with residual but stable disease, the decision gets harder. Some doctors recommend continuing beyond two years if the patient is tolerating the drug, particularly in cancers like lung cancer where the CheckMate 153 data suggested a benefit to ongoing treatment. Others weigh the accumulating side-effect risk and financial strain against the uncertain benefit of another year of infusions.

When Side Effects Force an Early Stop

Not everyone gets to choose when they stop. Immunotherapy works by releasing the brakes on the immune system, and that same mechanism can cause the immune system to attack healthy tissues. These immune-related side effects range from mild skin rashes and fatigue to serious inflammation of the lungs, liver, colon, or endocrine glands. When a severe reaction occurs, treatment is typically paused and sometimes permanently discontinued.

A real-world study of non-small-cell lung cancer patients in the UK who stopped treatment due to severe side effects found that their median overall survival after the first immune-related reaction was about 16 months. Patients who had received more than four cycles of immunotherapy or had been on treatment for more than roughly three months before the reaction hit tended to fare better than those who experienced toxicity very early in treatment.⁴ That makes intuitive sense: if the drug has had enough time to activate a meaningful immune response before it has to be stopped, the anti-cancer effect may persist even after the infusions end.

The durability of the immune response is one of the genuinely remarkable features of these drugs compared to traditional chemotherapy. Chemotherapy generally stops working the moment you stop giving it, because it directly poisons dividing cells. Immunotherapy, by contrast, trains the immune system to recognize the tumor. Once that recognition is established, it can sometimes continue even without further drug doses. That is why some patients who stop early due to side effects still have lasting responses.

What Happens After You Stop

The biggest fear patients have about stopping immunotherapy is that the cancer will come back. The data on this is reassuring for many, but not for everyone. A study following 567 advanced melanoma patients who had achieved long-term disease control on immunotherapy, defined as not needing a new treatment within three years of starting, found that among those who had no progression at all in the first three years, only about 8% experienced a late recurrence afterward. For a smaller group who had some early progression that was managed without changing treatment, the late recurrence rate was higher, around 22%.⁵

Those numbers are encouraging, especially for the large majority who had clean responses in the first three years. But they also mean that ongoing surveillance matters. Late recurrences do happen, even years out, and catching them early gives the best chance of successful retreatment. Most oncologists follow patients with regular imaging and blood work for years after stopping, with the schedule gradually becoming less frequent over time.

Retreatment When Cancer Returns

If cancer does recur after a patient has stopped immunotherapy, one of the natural questions is whether the same drug can work again. The evidence on this is still limited but cautiously positive for some patients. A retrospective study of metastatic cervical cancer patients who were retreated with immunotherapy after previously responding and then progressing found that about 27% achieved a partial response and another 20% had stable disease. The overall disease control rate was close to half. Median progression-free survival on retreatment was about 3 months, and median overall survival was about 8 months.⁶

Those numbers are modest compared to initial treatment, but they suggest that the door is not necessarily closed once immunotherapy has been tried. The response to retreatment likely depends on why the cancer returned. If the tumor mutated to evade immune detection entirely, retreatment with the same drug is less likely to work. If the immune response simply faded over time without the ongoing stimulation of the drug, re-starting treatment can sometimes reactivate it. This distinction is an area of active research, and there are not yet reliable ways to predict in advance which patients will benefit from a second round.

Blood Tests That Help Guide the Decision

One of the more promising tools for deciding when it is safe to stop treatment involves circulating tumor DNA, small fragments of DNA shed by cancer cells into the bloodstream. In a study of advanced melanoma patients who had to stop combination immunotherapy due to side effects, researchers measured whether these DNA fragments were detectable at the time of stopping. The results were striking: among patients who had detectable circulating tumor DNA when they stopped, seven out of eight went on to have their cancer progress. That gave the test very high specificity for predicting who would relapse, around 94%.⁷

The flip side was less clean. Among patients with no detectable tumor DNA, about a third still progressed, partly because brain metastases can grow without shedding much DNA into the blood. So a negative test is reassuring but not a guarantee. Still, this kind of blood-based monitoring represents the direction the field is heading: rather than relying on arbitrary time cutoffs, doctors want tools that tell them whether the cancer has been truly eliminated or is just lurking below the detection threshold of a CT scan.

Reduced-Frequency Dosing as a Middle Ground

Some researchers are exploring whether patients who have responded well can keep the benefit of ongoing treatment while reducing how often they come in for infusions. Early data from phase I studies showed that a single dose of nivolumab keeps the target receptor occupied for more than three months. Building on that, clinicians have tried spacing doses out to every two to three months instead of the usual every two to four weeks, specifically to extend treatment duration beyond the traditional two-year mark without the full burden of frequent visits.⁸

This approach is appealing because it acknowledges the uncomfortable middle ground many patients occupy: their cancer is controlled but not clearly cured, stopping feels risky, yet continuing at full frequency is disruptive and expensive. Reduced-frequency dosing is still being studied in formal trials, but it represents a practical compromise that some cancer centers are already offering to selected patients.

Combination Therapy and Duration

Immunotherapy is increasingly used alongside chemotherapy rather than alone, and that changes the duration picture in important ways. In advanced endometrial cancer, a meta-analysis of large phase III trials found that adding immunotherapy to chemotherapy improved progression-free and overall survival significantly. The combination came with a modest uptick in severe side effects, though serious adverse events did not increase significantly.⁹

In most combination regimens, the chemotherapy component has a fixed number of cycles, typically four to six, after which patients continue on immunotherapy alone as maintenance. This maintenance phase can last up to two years or longer, depending on the protocol. The combination approach has become the new standard in several cancer types, including certain lung cancers, bladder cancer, and endometrial cancer, and the question of how long to continue the maintenance immunotherapy mirrors the same uncertainties that exist for immunotherapy given on its own.

How Age Affects the Conversation

Older adults make up a large share of cancer patients, and there are theoretical reasons to think immunotherapy might work differently as the immune system ages. The immune system gradually becomes less responsive over the decades, a process sometimes called immunosenescence, and some reports have suggested this could reduce how well immunotherapy drugs work in older patients.¹⁰

In practice, however, the picture is more nuanced. Many of the landmark immunotherapy trials included patients in their 70s and 80s, and subgroup analyses have generally not shown dramatically worse outcomes for older patients compared to younger ones. The biology-driven approach to understanding age-related immune changes is still being worked out, and some researchers have argued that the specific immune alterations of aging might actually create opportunities for more tailored immunotherapy strategies rather than simply reduced efficacy.¹¹ Where age does clearly matter is in the tolerance of side effects. Older patients are more likely to have other health conditions that make immune-related toxicity harder to manage, and that can lead to earlier discontinuation regardless of how well the cancer is responding.

The Financial Weight of Open-Ended Treatment

Duration decisions do not happen in a clinical vacuum. Immunotherapy drugs are among the most expensive medications in oncology, with annual costs often running into six figures. A study of cancer survivors on Medicare found that receiving a high-cost immunotherapy drug was associated with a roughly 7 percentage-point increase in the likelihood of being unable to afford medical care compared to survivors who did not receive these drugs.¹² There were also trends toward patients skipping prescribed medications and accumulating household debt, although those associations did not reach statistical significance in the study.

For patients paying out-of-pocket costs through copays and coinsurance, every additional month of treatment adds up. This creates a real tension between the desire to continue treatment for as long as it might be helping and the financial reality of doing so. Some patients and their oncologists factor cost into the stopping decision explicitly, especially when the cancer appears well-controlled and the marginal benefit of additional months is uncertain. Patient assistance programs and copay foundations help bridge the gap for some, but they are not universally available and can be difficult to navigate.

The Psychological Side of Stopping

Even when the medical evidence supports stopping immunotherapy, many patients struggle emotionally with the transition. The drug has been keeping them alive, or at least that is how it feels, and walking away from it can trigger intense anxiety. Research on fear of cancer recurrence in lung cancer patients found that those with higher levels of this fear reported worse quality of life and, interestingly, appeared to have worse immunotherapy outcomes as well.¹³ While that study was conducted during a period of heightened anxiety due to COVID-19, the broader point resonates with what oncologists see routinely: patients who are terrified of stopping treatment often need as much support during the transition off therapy as they did during treatment itself.

Many cancer centers now incorporate structured survivorship planning into the end-of-treatment process, including clear surveillance schedules, education about what symptoms to watch for, and sometimes referrals for psychological support. Knowing that there is a concrete monitoring plan, and that retreatment is an option if needed, can make the prospect of stopping feel less like being abandoned and more like graduating to a new phase of care.

CAR T-Cell Therapy and Other Immunotherapy Types

The discussion so far has focused on immune checkpoint inhibitors, which are the most common form of immunotherapy and the type most patients are asking about when they wonder how long treatment lasts. But immunotherapy is a broad category, and other approaches have very different duration profiles. CAR T-cell therapy, for example, involves a single infusion of genetically engineered immune cells rather than ongoing drug administration. In some cases, these modified cells have been detected circulating in patients’ blood months after a single dose.¹⁴ The treatment itself is brief, though the monitoring and management of side effects can extend for weeks or months.

Cancer vaccines, bispecific antibodies, and cytokine therapies each have their own treatment timelines as well. Some are given for a set number of doses, others are maintained indefinitely. The trend across the field is toward combining these modalities, and as combinations become more common, the question of total treatment duration becomes even more complex. A patient might receive chemotherapy plus a checkpoint inhibitor for six months, then maintenance immunotherapy for two years, then surveillance. Or they might receive a checkpoint inhibitor that stops working and switch to a combination of two different immunotherapy drugs. The path is rarely a straight line, and the “how long” question often needs to be revisited at multiple decision points along the way.